Sort by Year:
Sort by Division:
11/12/14
Par Pharmaceutical Announces First FDA Approval of Vasostrict™ (vasopressin injection, USP)
11/05/14
Par Pharmaceutical Announces Quarterly Conference Call
09/30/14
Par Pharmaceutical Begins Shipment of Generic Exforge®
09/08/14
Par Pharmaceutical Resumes Shipment of Generic Precedex® Injection
08/06/14
Par Pharmaceutical Announces Quarterly Conference Call
07/09/14
Par Pharmaceutical Begins Shipment of Fluphenazine Decanoate Injection, USP
06/10/14
Strativa Pharmaceuticals Announces FDA Approval of Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device
05/28/14
Par Pharmaceutical Statement on Brevital® Sodium
05/07/14
Par Pharmaceutical Announces Quarterly Conference Call
04/07/14
Par Pharmaceutical Begins Shipment of Potassium Chloride Extended-Release Capsules
04/01/14
Par Pharmaceutical Names Terrance J. Coughlin Chief Operating Officer
03/13/14
Par Pharmaceutical Announces Fourth Quarter and Full Year 2013 Conference Call
02/20/14
Par Pharmaceutical Names Antonio R. Pera Chief Commercial Officer
01/21/14
Par Pharmaceutical to Acquire JHP Pharmaceuticals
01/16/14
Par Pharmaceutical Begins Shipment of Generic Lanoxin®
11/20/13
Par Pharmaceutical Begins Shipment of Generic Focalin XR® Capsules
10/24/13
Par Pharmaceutical’s Karen O’Connor Receives 2013 Cardinal Health Supply Chain Excellence Award
10/07/13
Par Pharmaceutical Begins Shipment of Generic Kapvay®
09/25/13
Par Pharmaceutical Begins Shipment of Generic Glucotrol XL®
09/23/13
Par Pharmaceutical Begins Shipment of KHEDEZLA (desvenlafaxine)
08/20/13
Par Pharmaceutical Receives Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
08/05/13
Par Pharmaceutical Announces Quarterly Conference Call
07/31/13
Par Pharmaceutical’s Martin Wilson Named to New Jersey Law Journal’s
07/18/13
Par Pharmaceutical Begins Shipment of Generic Trilipix®
 First | Previous | Next | Last